Tips offered for safe, effective antimetabolite use

Article

Performing "safe surgery" remains as the sine qua non for using antimetabolites safely and effectively as an adjunct to trabeculectomy. However, there are some strategies that can be incorporated in the surgical technique to reduce the risk of complications resulting from the application of anti-scarring medication, said Richard K. Parrish, II, MD, at the World Ophthalmology Congress.

Performing "safe surgery" remains as the sine qua non for using antimetabolites safely and effectively as an adjunct to trabeculectomy. However, there are some strategies that can be incorporated in the surgical technique to reduce the risk of complications resulting from the application of anti-scarring medication, said Richard K. Parrish, II, MD, at the World Ophthalmology Congress.

"One cannot do a technically unsatisfactory filtration procedure and expect an anti-scarring medication to rescue a fundamental surgical error," said Dr. Parrish of the Bascom Palmer Eye Institute at the University of Miami in the United States. "Minimizing preoperative subconjunctival inflammation, surgical trauma, and immediate postoperative hypotony are concepts that were critical before we had anti-scarring agents and still are today."

However, experience with anti-scarring agents has taught several lessons. The first is the importance of never placing the filtration site inferiorly. In addition, in order to create a more diffuse posterior bleb, the flap should be fornix-based, not limbus-based, and the intraoperative mitomycin-C should be applied over a larger area (3 or 4 clock hours) versus a more limited region.

Other safety considerations include use of intraoperative 5-fluorouracil 50 mg/mL for 5 minutes as an alternative to mitomycin-C in older Caucasians undergoing primary surgery. If the choice is made to use mitomycin-C in such patients, then a lower concentration - 0.2 or 0.4 mg/ml versus 0.5 mg/mL - and for a shorter exposure time - 2 minutes versus 5 minutes - might also be considered to reduce the likelihood of creating a very thin, avascular conjunctiva.

Dr. Parrish also noted that in his personal technique, he uses a cellulose sponge to absorb any excessive mitomycin-C prior to irrigation in the hopes of preventing distribution of the agent over the surgical field.

"I have no evidence this is beneficial, but it seems to make good sense," he said.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.